Current hypertension treatment possibilities and tactics in patients with comorbidities. The role of selective imidazoline receptor agonists. Expert opinion
Authors:
- T. V. PecherinaTPT. V. Pecherina
- G. A. ChumakovaGCG. A. Chumakova
- Yu. I. GrinshteinYGYu. I. Grinshtein
- O. Yu. DonirovaODO. Yu. Donirova
- N. V. ZakharchukNZN. V. Zakharchuk
- V. V. KashtalapV. V. Kashtalap
- T. A. PetrichkoTPT. A. Petrichko
- L. I. SyromyatnikovaLSL. I. Syromyatnikova
- O. V. FedorishinaOFO. V. Fedorishina
- S. М. CherepeninSCS. М. Cherepenin
Open Access
- 11 November 2025
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 24 (9) , 4609
Abstract
Hypertension (HTN) is a serious public health problem. Despite advances in diagnosis and public awareness, the percentage of controlled cases remains low, especially among men and the elderly. The main challenges are related to comorbidities such as obesity, diabetes, chronic kidney disease, and obstructive sleep apnea, which worsen the prognosis and increase the risk of cardiovascular events. The approach to HTN treatment should be individualized and take into account specific disease phenotypes and comorbidities. It is important to identify patients with increased sympathetic nervous system activity, as this group experiences the greatest difficulties in blood pressure control. Moxonidine, a centrally acting agent, selectively stimulates imidazoline receptors in the brain, causing a decrease in sympathetic activity and effective reduction in blood pressure. The need for a personalized approach to HTN therapy is driven by the growing number of patients with multiple comorbidities and complex pathogenesis. New approaches, including early initiation of combination therapy and targeted management of metabolic risk factors, will reduce cardiovascular morbidity and mortality. Moxonidine plays a key role within antihypertensive medications due to its unique mechanism of action and ability to positively impact a wide range of HTN-related pathologiesKeywords
This publication has 44 references indexed in Scilit:
- 2024 ESC Guidelines for the management of elevated blood pressure and hypertensionEuropean Heart Journal, 2024
- Obstructive sleep apnea -related hypertension: a review of the literature and clinical management strategyHypertension Research, 2024
- The Pathophysiology, Prognosis and Treatment of Hypertension in Females from Pregnancy to Post-menopause: A ReviewCurrent Heart Failure Reports, 2024
- Addressing global disparities in blood pressure control: perspectives of the International Society of HypertensionCardiovascular Research, 2022
- Ambulatory blood pressure monitoring profiles in a cross-sectional analysis of a large database of normotensive and true or suspected hypertensive patientsRevista Portuguesa de Cardiologia, 2018
- The data monitoring experience in the MOXCON trialEuropean Heart Journal, 2004
- Adverse Mortality Effect of Central Sympathetic Inhibition with Sustained-Release Moxonidine in Patients with Heart Failure (MOXCON)European Journal of Heart Failure, 2003
- Effects of moxonidine on sympathetic activity, and metabolic and hemodynamic variables in obese hypertensive patientsAmerican Journal of Hypertension, 2002
- Moxonidine Effect on Microalbuminuria, Thrombomodulin, and Plasminogen Activator Inhibitor-1 Levels in Patients with Essential HypertensionCardiovascular Drugs and Therapy, 1998
- Effective Antihypertensive TherapyJournal of Cardiovascular Pharmacology, 1996